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INTRODUCTION 
 Colorectal cancer ranks second among the most common tumours of the 
world according to world cancer report 2000.
[59]
 There is worldwide variation in 
the distribution of intestinal neoplasm, which appear largely due to exogenous 
factors rather than genetic.
[52]
  
 Colorectal carcinomas are uncommon in our country when compared with 
the western world. The incidence in India is about 7 / 100000.
[18] 
 Curiously the small intestine is an uncommon site for tumour, despite its 
great length and vast pool of dividing cells.
[9]
 Small bowel tumours account for 1-
2% of all gastrointestinal neoplasms.
[36]
 Small intestine tumours are usually 
asymptomatic or present with vague symptoms. If a small intestinal tumour is 
symptomatic there is 75% chance that it is malignant. The symptoms when present 
are usually mild and chronic. This is because of distensibility of small bowel. 
Intestinal obstruction when present is chronic and intermittent. Bleeding from the 
tumours though present in 25% is usually mild. 
 Majority of Colorectal carcinomas remain asymptomatic for years. They 
most often present with fatigue and weakness as these bulky lesions bleed readily 
and cause anemia.
[9] 
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 The treatment of choice for colorectal carcinoma is surgical resection. The 
postoperative outcome, prognosis and need for adjuvant therapy rely on the 
pathological assessment of resected specimen. 
 The vital elements of the pathological assessment of colorectal carcinoma 
specimen include pathological determination of TNM stage, tumour type, 
histological grade, resected margin and vascular invasion.
[13] 
In this retrospective study of intestinal tumours, incidence with respect to 
age, sex, site, and histomorphological features of various tumours were studied. 
 The present study also evaluates the role of tumour suppressor gene 
protein p53 in intestinal neoplasms and its prognostic value in colorectal 
adenocarcinomas. 
 The recent literature regarding intestinal tumours were also reviewed 
and correlated. 
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AIM OF THE STUDY 
Specimens were analysed to find out:- 
1.  The incidence of intestinal neoplasms. 
2. To evaluate the age, sex and site distribution of intestinal neoplasms. 
3. To evaluate the histopathological features of intestinal neoplasms. 
4. To assess the level of expression of p53 in intestinal neoplasms. 
5. To correlate the level of P53 expression with the stage of the colorectal 
adenocarcinomas and to assess its prognostic value in colorectal 
adenocarcinomas. 
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MATERIALS AND METHODS 
Out of 11891 cases reported totally at Thanjavur medical college, 111 cases of 
intestinal neoplasms was diagnosed during the period of January 2010 to June 
2012 were included in this study. 
 Out of 111 specimens 62 were resected specimens and 49 were endoscopic 
biopsies. Detailed histories with attention to age, sex, symptoms, colonoscopic 
findings, specific site of lesions were analysed. 
 The endoscopic biopsy materials were submitted intoto for routine 
histopathological examination. Multiple bits from the tumours in resected 
specimens and the adjacent resected margins were submitted as per standard 
guidelines for histopathological study. 
 
HISTOPATHOLOGICAL STUDY OF INTESTINAL NEOPLASMS: 
 All the specimens were fixed in 10% neutral formalin and were subjected to 
histopathological examination. Sections of 3-5µ thickness were made and routine 
staining with hematoxycilin and eosin was done (Appendix 1). 
 Staging of colorectal adenocarcinoma was done according to TNM staging. 
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p53 IMMUNOEXPRESSION: 
 A total of 30 cases of colorectal adenocarcinomas and 7 cases of small 
intestinal neoplasms were selected for studying the p53 expression. Tissue sections 
of 4μ thickness were fixed in formalin, paraffin embedded and stained with 
antibody directed against p53 antigen using an advanced polymer staining system. 
 Staining was performed according to the immunohistochemical staining 
protocol (Appendix 2). Under 400X magnification tumour cells were calculated by 
counting the number of brown stained tumour nuclei among the total number of 
cells in the intensely stained area and expressed in percentage. 
p53 immunostaining was done. For small intestinal malignancy, all p53 
positive nuclei were counted and the following semi-quantitative method was used: 
[±] – negative or equivocal (5% positive cells), [+] – weak\moderate (5-50% 
positivity) and [++] – intensely positive (>50% positivity).[15] For large intestinal 
malignancy, the slide was scored as positive if ≥10% of malignant nuclei were 
stained and was scored as negative if <10% of the nuclei were stained. While if 
fewer than 10% of the nuclei were stained, the slide was scored as negative.
[28]
 The 
statistical analysis was performed to determine whether p53 protein expression was 
correlated with the stage of the colorectal adenocarcinomas. Statistical analysis 
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was carried out with the aid of Chi-square test (Java script package). P value of 
less than 0.05 was taken to indicate statistical significance. 
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REVIEW OF LITERATURE 
HISTORICAL ASPECTS 
 Neoplasms of the small intestine have been very rare and first recognized in 
1655. Neoplasm of small intestine, when Wesner reported a case of 
leiomyosarcoma
[73]
, was first clinically reported in 1765. Carcinoids are common 
tumours of intestine and appendix. The cell of origin of these tumours was 
described by Nicholas kulchitsky
[54]
.  
In 1926, Dukes noted the association between polyposes of the colon and 
carcinoma. In 1940, he gave a system for grading carcinoma of colon based on the 
extent of invasion and lymphatic spread
 [21,73]
. In 1977 the WHO proposed a 
scheme for histological typing of colorectal tumours.
[74] 
ANATOMY
[8,20] 
SMALL INTESTINE 
 It extends from the pylorus to ileocaecal junction and is about six meters in 
length. It is divided into  
 Duodenum 
 Jejunum 
 Ileum 
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DUODENUM: 
 It is mostly retroperitoneum except at its two ends where it is suspended by 
folds of peritoneum. It is 25 inches long and extends from pylorus to duodeno-
jejunal flexure. 
JEJUNUM AND ILEUM: 
 They are suspended from the posterior abdominal wall by the mesentry. The 
jejunum constitutes the upper 2/5
th
 of the mobile part, while the ileum constitutes 
the lower 3/5
th
. The jejunum begins at duodeno-jejunal flexure and ileum ends at 
ileo-caecal junction. 
 
LARGE INTESTINE 
 It extends from ileo-caecal junction to the anus. It is about 1.5 metre long 
and is divided into caecum, the ascending colon, the transverse colon, the 
descending colon, the sigmoid colon, the rectum and the anal canal. In the angle 
between the caecum and the ileum, there is a narrow diverticulum called the 
vermiform appendix. The greater part of large intestine is fixed, except for 
appendix, transverse colon and sigmoid colon. 
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HISTOLOGY 
The wall of the gastrointestinal tract is made up of the following layers: 
A. Mucous membrane 
 Lining epithelium 
 Lamina propria 
 Muscularis mucosa 
B. Submucosa 
C. Muscularis propria 
D. Serosa 
SMALL INTESTINE: 
 The mucosa shows villi and crypts lined by columnar cells. In ileum the 
entire lamina propria is infiltrated by lymphocytes forming follicle called Peyer‟s 
patch. The submucosa in duodenum has Brunner‟s glands lined by mucus secreting 
columnar cells, whereas in jejunum occasional lymphoid nodule may be present. 
The muscularis propria has inner circular and outer longitudinal layers of smooth 
muscles and is covered by the serosa. 
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LARGE INTESTINE: 
 The mucosa shows numerous crypts lined by columnar cells, amongst which 
are numerous goblet cells. The muscularis mucosa, submucosa and circular muscle 
coat are similar to small intestine. However the longitudinal muscle coat is 
gathered into three thick bands called taenia coli. 
 
SMALL INTESTINAL TUMOURS 
CLASSIFICATION (WHO): 
Epithelial tumours 
 Adenoma 
 Villous 
 Tubular 
 Tubulovillous 
 Intraepithelial neoplasia(dysplasia) 
 Low-grade glandular intraepithelial neoplasia 
 High-grade glandular intraepithelial neoplasia 
 Carcinoma 
 Adenocarcinoma 
 Signet-ring cell carcinoma 
22 
 
 Mucinous adenocarcinoma 
 Small cell carcinoma 
 Squamous cell carcinoma 
 Medullary carcinoma 
 Adenosquamous carcinoma 
 Undifferentiated carcinoma 
 Carcinoid 
 Gastrin cell tumour, functioning or non functioning 
 EC-cell, serotonin-producing tumour 
 Somatostatin cell tumour 
 Gangliocytic paraganglioma 
 L-cell, giucagon-like peptide and PP/PYY producing neoplasm 
 Mixed carcinoid-adenocarcinoma 
 Others 
Non-epithelial tumours 
o Leimyoma 
o Leimyosarcoma 
o Lipoma 
o Gastro intestinal stromal tumour 
o Kaposi sarcoma 
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o Angiosarcoma 
o Others 
Malignant lymphomas 
 Immunoproliferative small intestinal disease 
 Mantle cell lymphoma 
 Western type B-cell lymphoma of MALT 
 Burkitt lymphoma 
 Diffuse large B-cell lymphoma 
 Atypical Burkitt lymphoma 
 Enteropathy associated T-cell lymphoma 
Secondary tumours 
Polyps 
 Peutz-jeghers 
 Juvenile 
 Hyperplastic 
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INCIDENCE: 
Small bowel tumours are relatively rare and constitute only 1-2% of all GI 
tumours, inspite of constituting 75% of the length and 90% of the mucosal surface 
of the alimentary tract. Approximately 2/3
rd
 of small bowel tumours are malignant. 
Mortality in small bowel neoplasm largely depends upon the histological 
subtypes and overall it was estimated to be 1040 deaths per year worldwide.
[4] 
Over 40 different histologically distinct tumours are known to be arising 
from the small intestine. However over 95% of these cases are adenocarcinoma, 
carcinoid, GIST or lymphoma.  
The incidence of each histological type is adenocarcinoma – 24-44%, 
carcinoid tumour – 20-42%, sarcoma or GIST – 9%, lymphoma – 12-27%. 
Adenocarcinoma and carcinoid tumours are the most common histological 
types.
[85]
 The prevalence of asymptomatic tumours is much higher than predicted 
by the overall incidence reported.
[10]
 There is an overall increase in incidence of 
adenocarcinoma and carcinoid tumours in recent years, particularly prominent in 
black males.
[36,47] 
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ETIOLOGY: 
 Genetic and environmental conditions predispose to cancer of the small 
intestine. 
PREDISPOSING CONDITIONS HISTOLOGICAL TYPE 
FAP Adenocarcinoma 
HNPCC Adenocarcinoma 
Celiac disease Adenocarcinoma, Lymphoma 
Gardner syndrome Adenocarcinoma, Desmoid  
Peutz-Jeghers  Adenocarcinoma, Hamartoma 
Crohn‟s disease  Adenocarcinoma  
AIDS  Lymphoma 
Neurofibromatosis Paraganglioma  
History of primary cancer in other sites Adenocarcinoma, Carcinoid 
  
PATHOGENESIS OF SMALL INTESTINAL CARCINOMA:
[33,39] 
 Tumours of Small bowel constitute to approximately 1 – 2% of the 
gastrointestinal malignancies. 
 Several theories have been forwarded to why small bowel is relatively 
protected from developing cancer:- 
 The contents of the small bowel are liquid and therefore have a much faster 
transit time resulting in less time for exposure to potential carcinogens. 
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 Most carcinogens act under acidic conditions. The neutral to alkaline pH of 
small bowel makes it less susceptible to malignancy. 
 Degradation of bile salts, which are carcinogenic in colon, is less due to 
decreased anaerobic bacteria in small intestine. 
 High folate levels, which are protective against carcinogenesis, due to high 
receptors for folate uptake in small intestine. 
 The small bowel has high levels of Benzopyrene hydroxylase, which leads 
to breakdown of Benzopyrene, a potential carcinogen used as food additive. 
 The small bowel has high level of lymphoid tissue especially IgA, which 
may be immunoprotective against development of cancer. 
 The small bowel has fewer stem cells, which may be the target for 
carcinogens. 
MOLECULAR GENETICS:
[44,50,55,78] 
 Tadashi Terada et al
[78]
 p53 mutations are present in most of the primary 
carcinoma of the small intestine. Few studies emphasize that the oncogenes namely 
p53, K-ras, erbB2 and Cyclin-D1 are all altered in a manner similar to large bowel 
tumours. The role of the adenoma carcinoma sequence and the epidemiological 
factors for both small bowel colorectal adenocarcinoma, remain similar. It seems 
that the molecular genetic changes are common to both the tumours.
[55]
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An alteration in the p53 gene is the most common genetic event in the 
sporadic small intestine adenocarcinoma.
[44]
 According to Ming Qing DU et al
[50]
, 
p53 inactivation commonly caused by mutation and allele loss has shown to play 
an important role in the early development and/or the late disease progression of 
any human tumours including lymphoid malignancies and thus may also be 
important in MALT lymphoma genesis. This study also suggested that the 
development of low grade MALT lymphomas were associated with partial 
inactivation of p53 while high grade tumours show complete inactivation. Strong 
p53 immunoreactivity is seen in high grade MALT lymphomas whereas focal p53 
positivity seen in low grade MALT lymphomas. 
CLINICAL FEATURES: 
 No specific signs or symptoms indicate the presence of small intestinal 
malignancy. The typical presentation for these cancers is often vague and nonfocal. 
Most of the tumours present with symptoms of abdominal pain, weight loss and 
fatigability. These tumours can cause obstruction.
[29]
  
A few generalizations can be made:- 
1. It appears that malignant lesions are symptomatic earlier as opposed to 
benign lesions, which are discovered incidentally.
[11]
 
2. Approximately half of all small bowel tumours present as an acute event, 
either as obstruction or perforation.
[14]
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EPITHELIAL TUMOURS 
ADENOCARCINOMA:
[33,39] 
Adenocarcinomas of the small intestine are much rare than carcinoma of the 
large bowel. Obstruction occurs late because of the fluid nature of small bowel 
contents and tumours are often diagnosed at an advanced stage and carries poor 
prognosis. Most of the carcinomas arise within a pre-existing adenoma. The 
periampullary region of the duodenum is the most common site and patients 
present with jaundice and bleeding. 
Macroscopic appearance: 
 The cancer may be flat, stenosing, ulcerative, infiltrative or polypoid. 
Usually cancer presents as an annular growth. 
Microscopic appearance: 
 Majority of the adenocarcinomas are well differentiated to moderately 
differentiated. Mucinous adenocarcinomas do occur but signet-ring cell carcinomas 
are relatively rare and should be distinguished from secondaries, notably from 
stomach. Ampullary adenocarcinomas are mainly intestinal in type. 
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CARCINOID TUMOUR:
[33,39,40] 
 They account for about 1/3
rd
 of small intestinal tumours. Classical carcinoid 
tumours arise in the duodenum or ileum, usually in the 5
th
 or 6
th
 decades and are 
slightly more common in women. They may metastasize to liver and mesenteric 
nodes. The tumour secretes 5-hydroxy tryptamine and other vasoactive amines. It 
may give rise to carcinoid syndrome. 
Carcinoid tumour may produce a variety of polypeptide hormones and are 
named according to the hormones produced. 
i. Gastrinoma – Leads to multiple peptic ulcers of stomach, jejunum and ileum 
(Zollinger Ellison syndrome). Usually occurs in duodenum. 
ii. Somatostatin cell tumour – Constitutes 15-20% of duodenal carcinoids. 
They are exclusively found in the region of ampulla of vater and are 
associated with Von Reckling Hausen disease. 
Macroscopic features: 
 These tumours invade bowel wall to produce narrowing of lumen and appear 
yellow in colour following formalin fixation. They are often multiple and may be 
associated with a synchronous non-endocrine gastro intestinal tumour. 
Microscopic appearance: 
 The tumour is composed of small cells with uniform round nuclei showing 
very frequent mitosis. Classical carcinoid consists of cells arranged in islands in 
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which the peripheral cells show palisading. Conspicuous among the peripheral 
cells are enterochromaffin cells. Other histologic patterns include trabecular, 
diffuse sheets, glandular structures, various intermediate forms and mixture of all 
these patterns. 
Prognostic factors: 
 Histologic features are not useful in determining the prognosis. They are 
slow growing and less aggressive than adenocarcinoma. The larger tumours are 
more aggresive and show extensive local spread with ulceration and necrosis. 
Special stains: 
 The EC cells are stained black with the argentaffin reaction, brick red by the 
diazo method and blue with lead hematoxylin. 
Immunohistochemistry: 
 Positive reactions for chromogranin, neuron-specific enolase and PGP 9-5 
will assist in the diagnosis of carcinoid tumour. 
Electron microscopy: 
 It will demonstrate characteristic electron dense neurosecretory granules. 
LYMPHOMAS:
[32] 
 Primary small intestinal lymphomas contribute a major proportion (30-50%) 
among all the malignant tumours of small bowel, of which MALT lymphomas 
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form the most frequent type. On the contrary, Burkitt lymphoma is the most 
common tumour arising from the ileo-caecal region. 
Burkitt lymphoma of small bowel: 
 Microscopically the neoplasm consists predominantly of intermediate sized 
cells admixed with neumerous tangible body macrophages. Tumour shows high 
mitotic activity. 
Immunohistochemistry:  
 CD10, CD20, CD22 and CD79a – Positive  
 CD5 and CD23 – Negative  
METASTATIC TUMOURS:  
 Metastatic tumours of small intestine are most frequently melanoma, 
carcinoma of lung, breast, colon and kidney. 
Metastatic melanoma:
[45] 
 Melanoma is composed of melanocytes of neuroectodermal origin. The most 
common metastatic tumour found in the gastrointestinal tract is malignant 
melanoma, of which the most frequently involved sites include small bowel (50%), 
colon (32%), and anorectum (25%). It presents as solitary or multiple polypoid 
lesions in the small intestine. 
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NON EPITHELIAL TUMOURS OF SMALL INTESTINE
[33,39] 
GIST: 
 Gastrointestinal stromal tumours are mesenchymal neoplasms that express c-
kit. With rare exception 1/4
th
 of GIST occurs in small intestine. The cell of origin is 
interstitial cell of cajal. They present clinically with pain, discomfort, obstruction 
or bleeding. 
Macroscopic features: 
GISTs are usually solitary, rounded or ovoid mass varying in size range from 2cm-
20cm. On cross section they are circumscribed, lack a true capsule and reveal pink 
or grey cut surface with rubbery consistency. 
Microscopic features: 
 They are categorized into 
1. Spindle cell type 
2. Epitheloid type 
3. Mixed type 
Immunohistochemistry: 
 Diagnosis of GIST is based on immunoreactivity for c-kit (CD117). Upto 60 
– 70% of cases show expression of CD34 and 30 – 40% for SMA. 
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LIPOMA:
[35] 
 Lipomas are rare but well recognized tumours of small and large intestine. 
Grossly appear as mass protruding into the lumen. Histologically the lesion 
consists of mature adipose tissue with various amounts of fibrous tissue. 
 
LARGE INTESTINAL TUMOURS 
COLORECTAL CARCINOMA 
CLASSIFICATION (WHO): 
Epithelial tumours 
 Adenoma 
 Tubular  
 Villous 
 Tubulovillous 
 Serrated  
 Intraepithelial neoplasia(dysplasia) 
 Low-grade glandular intraepithelial neoplasia 
 High-grade glandular intraepithelial neoplasia 
 Carcinoma 
 Adenocarcinoma 
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 Small cell carcinoma  
 Mucinous adenocarcinoma 
 Squamous cell carcinoma 
 Signet-ring cell carcinoma  
 Medullary carcinoma  
 Adenosquamous carcinoma 
 Undifferentiated carcinoma 
 Carcinoid (well differentiated endocrine neoplasm) 
 EC-cell, serotonin-producing tumour  
 L-cell, giucagon-like peptide and PP/PYY producing neoplasm  
 Mixed carcinoid-adenocarcinoma 
 Others 
Non-epithelial tumours 
 Lipoma  
 Leimyoma  
 Leimyosarcoma 
 Gastro intestinal stromal tumour 
 Kaposi sarcoma 
 Angiosarcoma 
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 Malignant melanoma 
 Others 
Malignant lymphomas 
 Mantle cell lymphoma 
 Marginal zone B-cell lymphoma of MALT 
 Diffuse large B-cell lymphoma  
 Burkitt lymphoma 
 Atypical Burkitt lymphoma 
 Others  
Secondary tumours 
Polyps 
o Hyperplastic  
o Peutz-jeghers  
o Juvenile 
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INCIDENCE:
 
 Colorectal carcinoma exhibits at least a 25 fold variation in occurrence 
worldwide. It is most common in the industrialized countries of western world and 
Eastern Europe, North America, Newzealand and Australia, while its incidence is 
low in Africa and Asia.
[24] 
ETIOLOGY:
[24] 
 Individuals at high risk of developing colorectal carcinoma are:- 
 History of colorectal adenoma 
 Family history of colorectal carcinoma 
 Family history of Hereditary non polyposis colon cancer 
 Patients with Familial Adenomatous Polyposis, Gardner syndrome, Old field 
syndrome, Turcott syndrome, Zanca syndrome, Peutz-Jeghers syndrome, 
Juvenile polyposis syndrome, Ulcerative colitis, Crohn‟s disease 
People taking high calorie diet along with sedentary life style habits are 
more prone to develop colorectal carcinoma. Statistical studies show that smoking, 
alcohol and animal fat consumption are the major predisposing factors. 
 Family history and physical inactivity are not strong contributions to the 
etiology of rectal cancers.
[84]
 A rare but well recognized risk factor in colorectal 
tumour is therapeutic pelvic irradiation.
[32]
 Non-steroidal anti-inflammatory drugs 
are known to be protective against colorectal carcinoma.
[61] 
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PATHOGENESIS OF COLORECTAL CARCINOMA:
 
 The majority of colorectal carcinoma develops sporadically (88-94%). The 
remainder occurs in high risk groups like hereditary cancer syndromes (e.g. 
HNPCC and FAP) and long standing inflammatory bowel disease.
[17] 
Genetic susceptibility: 
Among colorectal carcinomas, 5-15% is hereditary in nature. Various 
genetic disorders exist, that predispose individuals to colorectal cancer.
[19]
 
According to genetic susceptibility, the colorectal carcinomas are broadly 
classified into familial adenomatous polyposis coli (FAP) and hereditary non 
polyposis colon cancer (HNPCC).
[32] 
Molecular genetics: 
 Molecular genetics varies for both proximal and distal colonic tumours. 
Proximal colonic tumours are associated with microsatellite instability whereas the 
distal colonic tumours are related to specific chromosomal instability. 
 Majority colorectal tumours begin with a mutational inactivation of the APC 
suppressor gene. Then additional genetic alteration like inactivation of tumour 
suppressor gene such as p53 and activation of proto-oncogene such as ras, c-myc 
occurs. 
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CLINICAL FEATURES:
[9] 
 Few patients remain asymptomatic, being diagnosed during routine 
screening procedures. Anaemia and haematochezia are commonly seen in 
symptomatic individuals. Tumours in the proximal colon often grow as polypoid, 
exophytic masses; these tumours rarely cause obstruction. In contrast, carcinomas 
in the distal colon tend to be annular lesion and cause obstruction. Other symptoms 
include fever, abdominal pain, abdominal distension, malaise, weight loss, and 
tenesmus. Obstruction or perforation may complicate the clinical feature. 
HISTOPATHOLOGICAL FEATURES OF COLORECTAL CARCINOMAS 
ADENOCARCINOMA: 
Macroscopic features: 
Grossly most of the colorectal tumours present as either polypoid or 
ulcerative/infiltrating lesions. Mucinous adenocarcinomas exhibit a gelatinous, 
glaring appearance and often have areas with macroscopically visible layers of 
mucus. 
Microscopic features:
[32] 
 The characteristic feature of colorectal adenocarcinoma is invasion into the 
submucosa. Majority of the colorectal adenocarcinomas are gland forming 
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tumours. 90-95% of large bowel tumours are adenocarcinomas. 25% are well 
differentiated, 60% are moderately differentiated and 1.5% is poorly differentiated.  
 
Grading of Colorectal Adenocarcinoma
[69] 
Grade 
Descriptive 
nomenclature 
Criteria 
AJCC 
recommendation 
GX 
Grade cannot be 
assessed 
-- -- 
G1 Well differentiated 
95% of gland 
forming 
 
Low grade 
G2 
Moderately 
differentiated 
50% - 95% gland 
forming 
Low grade 
G3 
Poorly 
differentiated 
<50% gland 
forming 
High grade 
G4 Undifferentiated  
No apparent gland 
formation 
High grade 
 
 
MUCINOUS ADENOCARCINOMA:
[22,76] 
Mucinous adenocarcinomas, including signet ring cell cancer account for 
approximately 10% of colorectal cancers. Usually it affects younger individuals, 
often seen in the proximal colon and It presents at an advanced stage. Presence of 
>50% mucinous area must be necessary to designate it as mucinous 
adenocarcinoma. 
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There are two subtypes of mucinous adenocarcinoma –  
1. Signet ring cell carcinoma  
   2. Colloid carcinoma 
 
Signet-ring cell carcinoma:
 
 Signet-ring cell tumours account for approximately 1% of colorectal 
tumours. This designation is used if >50% of tumour cells contain  
intracytoplasmic mucin.
[25]
 This variant behaves very aggressively and it has a poor 
prognosis. Many of the patients are young and the disease clinically resembles 
inflammatory bowel disease. Both small cell and signet ring cell carcinoma are 
consistently been found to have an adverse effect on prognosis irrespective of its 
stage. 
[75] 
Colloid carcinoma:
[76] 
 Colloid carcinomas often arise in villous adenomas. These are very large 
bulky tumours with large mucinous areas. Diagnostic features are: 
1. Presence of abundant intraluminal mucin 
2. Stroma contain pools of mucin 
3. Superficial pools of mucin containing free lying ribbons or clusters of 
malignant cells.
[76]
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Histochemical, immunohistochemistry and electron microscopic features of 
colorectal adenocarcinoma:
[39,40] 
 Histochemically large majority of colorectal adenocarcinomas are positive 
for alcian blue stains. Immunohistochemically MUC1 and MUC3 are expressed by 
conventional adenocarcinoma while MUC2 by mucinous carcinoma. All colorectal 
adenocarcinomas express villin, CK, CDX2, TAG-72 and LEA. Electron 
microscopy shows presence of prominent collection of microfilaments running 
perpendicular to the cell membrane and entering the brush border.  
SMALL CELL CARCINOMA:
[39] 
 Small cell carcinoma comprises <1% of colorectal cancer. Histologically 
they are identical to small cell carcinoma of the lung. They have extremely poor 
prognosis and almost all cases have lymphnode and liver metastasis. 
SQUAMOUS AND ADENOSQUAMOUS CARCINOMA:
[39] 
 These tumours are extremely rare. They have been associated with ulcerative 
colitis, schistosomiasis and pelvic irradiation. 
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STAGING OF COLORECTAL CARCINOMA 
Once the diagnosis of colorectal carcinoma has been established by 
whatever method, accurate staging is of paramount importance in planning the 
surgical approach, in deciding whether neoadjuvant chemotherapy and 
radiotherapy is necessary and in determining the risk of recurrence and overall 
prognosis.
[31] 
 Numerous schemes have been developed to stage colorectal carcinomas. The 
depth of invasion and the presence or absence of lymphnode involvement are the 
two major determinants of all staging systems.
[24]
  
 In 1932, Dukes refined the Lockhart and Mummery classification devised in 
1926 and established the staging system that bears his name.  
DUKE’S STAGING SYSTEM [24] 
 Stage A – Tumour confined to the intestinal wall 
 Stage B – Tumour invading through the intestinal wall 
 Stage C – With lymphnode(s) involvement 
 C1 – Only the regional lymphnodes are involved 
 C2 – Nodes at the point of mesenteric blood vessel 
ligature are involved 
 Stage D – with distant metastasis 
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Another staging system formerly widely used is that described by Astler and 
Coller which represents modification of classification proposed by Duke‟s and 
Kirklin. 
ASTLER-COLLER STAGING SYSTEM
[43] 
 Stage A    : Tumour limited to the mucosa 
 Stage B1  : Tumour involving the muscularis externa but not penetrating it 
 Stage B2  : Tumour penetrating through the muscularis externa 
 Stage C1  : Tumour confined to the bowel wall with regional lymphnode  
                    metastases 
 Stage C2  : Tumour penetrating through the wall with regional lymphnode  
                    Metastases
 
 Stage D   : Distant metastases 
 
In 1954, Denoix proposed the TNM cancer classification system based on 
disease extent. This classification is compatible with the Duke‟s classification 
but it adds greater precision in the identification of some of the prognostic 
subgroups. 
 In the TNM system, the designation  
 T – The local extent of the primary tumour at the time of diagnosis, before 
the administration of treatment of any kind 
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 N – The status of regional lymphnodes 
 M – Distant metastasis including the non-regional lymphnodes. 
 p – Pathological determination of the TNM,[13]. 
 
Primary tumour (T) 

 pTx Primary tumour cannot be assessed 

 pT0 No evidence of primary tumour 

 pTis Carcinoma in situ (intraepithelial or intramucosal carcinoma) 

 pT1 Tumour invades the submucosa 

 pT2 Tumour invades the muscularis propria 

 pT3 Tumour invades through the muscularis propria into the 
subserosa or into the non-peritonealised pericolon or perirectal 
tissues 

 pT4 Tumour directly invades other organs or structures (T4a) or 
perforates the visceral peritoneum (T4b) 
Regional Lymphnodes (N) 

 pNx Regional lymphnodes cannot be assessed 

 pN0 No regional lymphnode metastasis 

 pN1 Metastasis in 1 to 3 lymphnodes 

 pN2 Metastasis in 4 or more lymphnodes 
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Distant Metastasis (M) 

 pMx Presence of distant metastasis cannot be assessed 

 pM0 No distant metastasis 

 pM1 Distant metastasis 
 
 
TNM Stage groupings 
Stage 0 Tis N0 M0 
Stage I 
T1 N0 M0 
T2 N0 M0 
Stage IIA T3 N0 M0 
Stage IIB T4 N0 M0 
Stage IIIA T1/T2 N1 M0 
Stage IIIB T3/T4 N1 M0 
Stage IIIC Any T N2 M0 
Stage IV Any T Any N M1 
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CARCINOID TUMOUR:
[39,40] 
 They can occur in any portion of large intestine but are more common in the 
rectum. Colorectal carcinoids are rarely associated with carcinoid syndrome. 
Macroscopic appearance: 
 It may appear as a flat and slightly depressed plaque or as a polypoid lesion 
which has yellow colour after formalin fixation. 
Microscopic appearance: 
 The tumour is characterized by small, uniform cells growing in a ribbon or 
festoon fashion in the stroma. The tumours are consistently argyrophilic but not 
usually argentaffinic. Immunohistochemically they stain for pan endocrine markers 
and for variety of peptide hormones. 
ADENOCARCINOID (GLANDULAR NEURO ENDOCRINE MIXED 
TUMOUR):
[88] 
 Colorectal GNMT is an uncommon entity affecting elderly patients with 
female to male ratio 1: 1.1 Histologically 58% of GNMT were classified as 
collision tumours and 42% were classified as composite tumours. Neuroendocrine 
and glandular components of the GNMT can show a spectrum of differentiation. 
Regardless of its percentage volume each component can metastasize separately. 
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Poorly differentiated component will likely metastasize and make an impact in 
prognosis.  
LARGE INTESTINE LYMPHOMA:
[25] 
Lymphomas of large bowel are relatively rare with the most common site 
involved being caecum followed by rectum. Diffuse large B-cell lymphoma form 
the most common type followed by MALT lymphoma. 
RECTAL MELANOMA:
[67,71] 
 Malignant melanoma of rectum constitutes about 1% of anorectal 
malignancies. eyes and skin are the two most frequent sites for melanoma followed 
by rectum. It is very aggressive usually starting from the 4
th
 decade, predominantly 
in women with an increased incidence in the 5
th
 or 6
th
 decade of life. Patient often 
presents with rectal bleeding and tenesmus. Prognosis is very poor. 
p53: 
The Tp53 (Tumour protein p53, also abbreviated as p53) gene is located in 
chromosome 17p13.1. It is the single most common target for genetic alteration in 
human tumours. It plays an important role in cell cycle control and in the induction 
of apoptosis. It has been described as “the guardian of the genome”, “the guardian 
angel gene”, and “the master watchman” referring to its role in conserving stability 
by preventing genome mutation. 
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 The p53 tumour suppressor gene is mutated in approximately 70-80% of 
colorectal carcinoma.
[9]
 Mutation or loss of p53 usually occurs at the time of 
transition from adenoma to carcinoma in the adenoma-carcinoma sequence. The 
frequency of p53 abnormalities increases with the progression of the lesion. 
Mutation of the p53 tumour suppressor gene is thought to play an important role in 
the progression of colorectal carcinoma and might therefore represent a clinically 
useful marker of prognosis. Immunohistochemical markers currently being 
investigated for their prognostic impact include proteins involved in the wide array 
of signaling pathways mediating colorectal tumour progression and metastasis. 
D.A. Spandidos et al
[15]
 in his study of 13 human small intestinal tumours for 
p53 using an immunohistochemical technique, found that p53 nuclear 
phosphoprotein is overexpressed in 46% of small intestinal tumours including 
lymphoma(1), angiosarcoma of the jejunum(1), leiomyosarcoma(1), 
adenocarcinoma of the small intestine(1) and metastatic adenocarcinomas(2) of the 
colon. Intense p53 expression was observed only in the MALT lymphoma and the 
two metastatic adenocarcinomas of the colon. These results indicate that the p53 
gene may be involved in the pathogenesis of small intestinal tumours. 
 Ge C, He S, Tian Y
[27]
 in their study of the relationship of p53 gene mutation 
with the occurrence and prognosis of small intestinal tumours, 75% of small 
intestine cancers showed p53 positivity. One out of 7 cases of small bowel 
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adenoma only one was positive for p53 protein. Normal tissue of intestine did not 
express p53 protein. The degree of tumor cell differentiation, invasion, metastasis 
and prognosis significantly correlated with the degree of p53 protein expression.  
Krugmann et al
[41]
 studied clinicopathological and immunohistochemical 
features of 144 cases of primary gastrointestinal lymphoma with sufficient clinical 
followup. The expression levels of p53 were studied for prognostic significance. 
The lymphomas were classified as diffuse large B cell lymphoma or MALT 
lymphoma. High p53 accumulation was more prevalent in diffuse large B cell 
lymphoma. p53 expression was important in the transformation of low grade 
MALT lymphoma and is an indicator for aggressive behavior in high grade 
tumours. 
Peter F. Rambau et al
[65]
 studied p53 immunoreactivity in 109 patients with 
colorectal adenocarcinoma using immunohistochemistry by the use of monoclonal 
antibody. Out of 109 patients, 61 cases (56%) expressed p53 protein in the nucleus 
of malignant cells. It was expressed more in left sided colonic tumours (p<0.05) 
and this could support the hypothesis that right and left colonic tumours have 
different pathogenesis and probably also responsible for difference in prognosis in 
these two topographic sites.  
Yuvan – Tzu Lan et al[87], in his study of 258 patients, reported that, p53 
overexpression was found in higher frequency in well to moderately differentiated 
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tumours than poorly differentiated tumours. p53 overexpression was more frequent 
in patients with non-mucinous type of colorectal carcinoma (39.0 Vs 29.2%, 
p=0.344) than mucinous type of colorectal carcinoma.  
T. Starzynska et al
[77]
, in his study, concluded that p53 expression correlates 
well with the stage of the disease and unfavourable outcome. P53 overexpression 
was seen in tumours which had invaded regional lymphnodes. The increased level 
of p53 was associated with early relapse and death.  
 George E. Theodoropoulos et al
[28]
 done a retrospective study of 164 
colorectal adenocarcinoma specimens for p53 and EGFR expressions. The 
conclusion was p53 protein overexpression was significantly associated with 
advanced tumour stage (p=0.004). 
Mohammad-Reza-Ghavam-Nasiri MD et al
[51]
, in his study of 100 
specimens for p53 protein using monoclonal antibody, concluded that p53 protein 
expression didn‟t show significant association with age, gender, site of tumour, 
histological type and stage of the disease.  
Scott et al
[72]
 analysed 52 colorectal carcinomas and found no correlation 
with p53 overexpression and several factors related to prognosis. 
Recently Campo et al
[7]
 in their study also found that p53 overexpression 
was not correlated with tumour grade, tumour stage in 64 cases of colorectal 
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adenocarcinomas. These authors concluded that p53 could not be used as 
prognostic marker.  
It is evident from the above studies, that p53 overexpression as a prognostic 
marker in colorectal adenocarcinoma is controversial. This may be due to the 
differences in the numbers of tumours examined or the different kind of materials, 
methods and antibodies used in various studies. 
In this study, the expression of p53 in various intestinal tumours received at 
the Department of Pathology, Thanjavur medical college has been studied and the 
results were compared with the above studies.  
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OBSERVATION AND RESULTS 
INCIDENCE: 
 Out of the 4286 neoplasms diagnosed totally, during the period of study 
(January 2010 – June 2012), there were 111 neoplasms arising in the intestine. 
Thus the annual incidence of intestinal neoplasms in our study was 2.6% (Table 1).  
TABLE – 1 
INCIDENCE OF INTESTINAL NEOPLASMS IN OUR STUDY 
Period 
Total No. of 
specimens 
Total 
neoplasms 
Intestinal 
neoplasms 
Incidence 
(%) 
Jan 2010 – 
June 2012 
11891 4286 111 2.6 
 
TABLE – 2 
INCIDENCE OF SMALL AND LARGE INTESTINE NEOPLASMS IN OUR 
STUDY 
Total No. of 
neoplasms 
Small intestine Large intestine 
No. of cases % No. of cases % 
111 11 10 100 90 
 
Of the 111 intestinal neoplasms, 100 cases were from the large intestine which 
contributes significantly for higher incidence with 90% (Table 2) (Chart 1). 
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TABLE – 3 
INCIDENCE OF BENIGN AND MALIGNANT NEOPLASMS 
TUMOUR 
TYPE 
BENIGN MALIGNANT 
Small intestine Large intestine Small intestine Large intestine 
NO. OF CASES 2 5 9 (0.3%) 95 (2.99%) 
 
Among 111 intestinal neoplasms 3/4
th
 was malignant. Large intestinal tumours 
constitute 2.99% and small intestinal tumours 0.3% of 3174 cases of malignant 
tumours (Table 3) (Chart 2). 
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TABLE – 4 
CLINICAL PRESENTATION OF SMALL INTESTINAL NEOPLASMS 
SYMPTOMS NO OF CASES % 
INTESTINAL OBSTRUCTION 8 73 
BLEEDING PER RECTUM 1 9 
ABDOMINAL MASS 1 9 
ABDOMINAL PAIN 1 9 
 
From the Table 4 (Chart 3), it is clear that most common clinical symptom of small 
intestinal neoplasm is intestinal obstruction (73%). 
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TABLE – 5 
SITE DISTRIBUTION OF SMALL INTESTINAL NEOPLASMS 
SITE NO OF CASES % 
DUODENUM 7 64 
JEJUNUM 2 18 
ILEUM 2 18 
TOTAL 11 100 
 
From Table 5 (Chart 4), it is clear that most of the small intestinal neoplasms arise 
from the duodenum (64%). 
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TABLE – 6 
AGE, SEX AND TYPE WISE DISTRIBUTION OF SMALL INTESTINAL 
NEOPLASMS 
 
From our statistical study data, it is inferred that the small intestinal neoplasms 
commonly occur in the 30 – 50 years of age group and show equal incidence in 
both the sexes (Table 6). Of small intestinal malignant tumours adenocarcinoma 
and lymphoma have equal incidence in our study (Table 6) (Chart 5). 
 
AGE 
(Yrs) 
MALIGNANT 
BENIGN 
ADENOCARCINOMA 
(36%) 
LYMPHOMA 
(36%) 
METASTATIC TUMOUR 
(9%) 
M F T M F T M F T M F T 
0-10 0 0 0 0 1 1 0 0 0 0 0 0 
11-20 0 0 0 0 0 0 0 0 0 0 0 0 
21-30 0 0 0 1 0 1 0 0 0 0 0 0 
31-40 0 2 2 0 0 0 0 0 0 0 1 1 
41-50 2 0 2 1 0 1 0 0 0 0 0 0 
51-60 0 0 0 1 0 1 1 0 1 0 0 0 
61-70 0 0 0 0 0 0 0 0 0 1 0 1 
TOTAL 2 2 4 3 1 4 1 0 1 1 1 2 
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TABLE – 7  
p53 EXPRESSION IN SMALL INTESTINAL TUMOURS 
S.NO BIOPSY NO HPE GRADE P53 
1 381/11 BURKITT LYMPHOMA 
 
- 
2 888/11 ADENOCARCINOMA II + 
3 1677/11 ADENOCARCINOMA II - 
4 2092/11 ADENOCARCINOMA I + 
5 4726/11 MALT-LYMPHOMA 
 
+ 
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TABLE – 8  
p53 EXPRESSION IN RELATION TO HISTOLOGICAL TYPES 
TUMOURS 
p53 
TOTAL 
+ % - % 
ADENOCARCINOMA 2 67 1 33 3 
LYMPHOMA 1 50 1 50 2 
 
In this study 60% of the small intestinal tumours revealed p53 positivity. 67% of 
the adenocarcinomas and 50% of the lymphomas showed immune reactivity for 
p53 protein (Table 8). 
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TABLE – 9 
CLINICAL FEATURES OF COLORECTAL TUMOURS 
SYMPTOMS NO OF CASES % 
BLEEDING PER RECTUM 55 55% 
LOSS OF WEIGHT 15 15% 
CONSTIPATION 9 9% 
INTERMITTENT CONSTIPATION AND LOOSE 
STOOLS 
12 12% 
INTESTINAL OBSTRUCTION 9 9% 
 
Table 9 (Chart 6) shows that, among the clinical features, bleeding per rectum was 
the most common clinical presentation (55%) of the colorectal tumours. 
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TABLE – 10 
COLONOSCOPIC FINDINGS OF COLORECTAL TUMOURS 
COLONOSCOPIC FINDINGS NO OF CASES % 
ULCEROPROLIFERATIVE 82 82 
POLYP 10 10 
NARROWING OF LUMEN 8 8 
TOTAL 100 100 
 
From Table 10 (Chart 7), it is evident that ulceroproliferative growth was the 
predominant (82%) gross feature in most of the colorectal tumours. 
 
TABLE – 11 
SITE DISTRIBUTION OF COLORECTAL TUMOURS 
SITE NO OF CASES % 
CAECUM 10 10 
ASCENDING COLON 8 8 
TRANSVERSE COLON 8 8 
DESCENDING COLON 0 0 
SIGMOID COLON 8 8 
RECTUM 66 66 
TOTAL 100 100 
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TABLE – 12 
SITE DISTRIBUTION OF COLORECTAL TUMOURS IN RELATION TO 
SEX 
SITE MALE FEMALE TOTAL 
CAECUM 2 8 10 
ASCENDING 
COLON 
6 2 8 
TRANSVERSE 
COLON 
7 1 8 
DESCENDING 
COLON 
0 0 0 
SIGMOID COLON 5 3 8 
RECTUM 44 22 66 
TOTAL 64 36 100 
 
From Table 11&12 (Chart 8&9), it is evident that rectum is the most common site 
of occurrence (66%) in both the sexes and colorectal tumours show male 
predominance. 
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TABLE – 13 
SITE DISTRIBUTION OF COLORECTAL TUMOURS IN RELATION TO 
AGE 
AGE 
(Yrs) 
SITE 
CAECUM 
ASCENDING 
COLON 
TRANSVERSE 
COLON 
DESCENDING 
COLON 
SIGMOID 
COLON 
RECTUM 
10-20 0 0 1 0 0 0 
21-30 0 1 0 0 1 1 
31-40 1 3 2 0 1 12 
41-50 2 2 1 0 3 20 
51-60 3 0 3 0 2 17 
61-70 4 2 0 0 0 14 
71-80 0 0 1 0 1 2 
TOTAL 10 8 8 0 8 66 
 
 
From Table 13 (Chart 10), it is inferred that rectum was the most common site of 
malignancy in all age groups. Majority of tumours were seen in the age range of 40 
– 60 years. 
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TABLE – 14 
PATHOLOGICAL TYPES OF COLORECTAL TUMOURS 
TUMOUR TYPE NO OF CASES % 
ADENOCARCINOMA 82 82 
MUCINOUS CARCINOMA 9 9 
SIGNET RING CELL 
CARCINOMA 
1 1 
NEUROENDOCRINE 
CARCINOMA 
1 1 
MELANOMA 1 1 
ADENOSQUAMOUS 
CARCINOMA 
1 1 
 
From Table 14 (Chart 11), it is inferred that adenocarcinoma is the most common 
histological type of colorectal tumours accounting for about 86% followed by 
mucinous adenocarcinoma (10%). 
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TABLE – 15 
HISTOLOGICAL GRADES OF COLORECTAL ADENOCARCINOMA 
GRADE NO. OF CASES % 
GRADE I 39 44 
GRADE II 36 40 
GRADE III 5 6 
MUCINOUS CARCINOMA 9 10 
TOTAL 89 100 
 
Table 15 (Chart 12) shows well differentiated adenocarcinomas (Grade I) is the 
most common histological grade, followed by the moderately differentiated 
adenocarcinomas (Grade II). 
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TABLE – 16 
AGE AND SEX DISTRIBUTION IN RELATION TO HISTOLOGICAL 
GRADES 
 
Table 16 (Chart 13) shows all the histological grades showing male predominance 
and majority in the age range of 40 – 60 years. 
AGE 
GRADE I GRADE II GRADE III 
MUCINOUS 
CARCINOMA 
TOTAL 
M F T M F T M F T M F T M F T 
10-20 0 0 0 0 0 0 0 0 0 1 0 1 1 0 1 
21-30 0 0 0 0 1 1 0 0 0 0 0 0 0 1 1 
31-40 7 1 8 2 2 4 2 0 2 1 3 4 12 6 18 
41-50 4 7 11 5 5 10 2 0 2 2 0 2 13 12 25 
51-60 10 4 14 7 1 8 1 0 1 1 0 1 19 5 24 
61-70 4 1 5 7 4 11 0 0 0 0 1 1 11 6 17 
71-80 1 0 1 2 0 2 0 0 0 0 0 0 3 0 3 
TOTAL 26 13 39 23 13 36 5 0 5 5 4 9 59 30 89 
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TABLE – 17    
STAGE DISTRIBUTION IN COLORECTAL ADENOCARCINOMA                                                                                                                                                                                                                                                                                                 
STAGE NO OF CASES % 
I 8 26 
II 7 22 
III 12 39 
IV 4 13 
TOTAL 31 - 
 
From our statistical data, it is inferred that, stage III colorectal adenocarcinoma 
was more frequent (39%) than other stages (Table 17).  
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TABLE – 18 
AGE AND SEX DISTRIBUTION IN RELATION TO STAGE 
 
AGE 
STAGE I STAGE II STAGE III STAGE IV 
M F T M F T M F T M F T 
10-20 0 0 0 0 0 0 1 0 1 0 0 0 
21-30 0 0 0 0 1 1 0 0 0 0 0 0 
31-40 1 0 1 1 1 2 1 0 1 2 0 2 
41-50 0 0 0 1 2 3 1 2 3 1 0 1 
51-60 4 1 5 0 0 0 2 1 3 1 0 1 
61-70 1 1 2 0 1 1 3 1 4 0 0 0 
TOTAL 6 2 8 2 5 7 8 4 12 4 0 4 
 
Stage I & II tumours were categorized as low stage & Stage III & IV were 
categorized as high stage (Table 18) (Chart 14). In this study, low stage tumours 
predominated in both sexes and the high stage tumours were common in males. 
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TABLE – 19 
p53 EXPRESSION IN COLORECTAL ADENOCARCINOMA 
S.NO HPE NO. GRADE STAGE p53 
1 3209/10 II IV + 
2 3333/10 I III + 
3 3460/10 I III + 
4 3484/10 II I - 
5 4044/10 I I - 
6 4192/10 II III + 
7 218/11 II III + 
8 364/11 I II - 
9 862/11 II III + 
10 1236/11 II II - 
11 1250/11 I IV + 
12 1645/11 I I + 
13 1689/11 
Mucinous 
adenocarcinoma 
II - 
14 2037/11 III IV + 
15 2124/11 II I - 
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S.NO HPE NO. GRADE STAGE p53 
16 2937/11 I I - 
17 3101/11 I III - 
18 3384/11 I IV - 
19 3461/11 II II + 
20 4073/11 
Mucinous 
adenocarcinoma 
II - 
21 4227/11 
Mucinous 
adenocarcinoma 
III - 
22 4289/11 II II + 
23 519/12 II III + 
24 610/12 I I - 
25 722/12 II II - 
26 1027/12 
Mucinous 
adenocarcinoma 
III + 
27 1189/12 I I + 
28 1522/12 II III + 
29 1992/12 II III - 
30 2120/12 II III + 
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TABLE – 20  
p53 EXPRESSION IN COLORECTAL ADENOCARCINOMA 
ADENOCARCINOMA 
p53 
TOTAL 
+ % - % 
CONVENTIONAL 
ADENOCARCINOMA 
15 57.7 11 42.3 26 
MUCINOUS ADENOCARCINOMA 1 25 3 75 4 
TOTAL 16 53.3 14 46.7 30 
 
In this study 53.3% of the colorectal adenocarcinomas showed p53 positivity. p53 
over expression  was more frequent in non-mucinous adenocarcinomas than in 
mucinous adenocarcinomas  (Table 20). 
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TABLE – 21 
 p53 EXPRESSION IN COLORECTAL ADENOCARCINOMAS IN 
RELATION TO STAGE 
STAGE 
p53 
TOTAL 
POSITIVE 
CASES 
% 
+ - 
I 2 5 7 28.57 
II 2 5 7 28.57 
III 9 3 12 75 
IV 3 1 4 75 
TOTAL 16 14 30 - 
 
For the purpose of statistical analysis stages I and II were considered as low stage 
tumours and stages III and IV were considered as high stage. The proportion of 
positively reacting colorectal tumours increases as the stage progresses. Statistical 
analysis using Chi- square test was done which revealed a P value of <0.05 ( X
2
 = 
4.74) which is statistically significant. Hence p53 expression is significantly 
correlated with the stage of tumour in colorectal adenocarcinoma (Table 21) (Chart 
15).  
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DISCUSSION 
Tumours of intestines are some of the common neoplasms encountered and 
they demonstrate an array of histological patterns, varied clinical presentations, an 
assortment of gross patterns and an immense variability in their prognosis.  
In our retrospective study, done during Jan2010 to June2012 at Thanjavur 
medical college and hospital, of 111 cases of intestinal neoplasms, 100 specimens 
were from large intestine and 11 specimens were from small intestine, the 
incidence is 2.6%. Of total malignancies large intestine constitutes 2.99% and 
small intestine 0.3%. This is in accordance with the study done by Ioannis Hatzaras 
et al.
[36] 
 However in India, these tumours are relatively rare but its incidence is 
increasing and varies from place to place.  
 Colorectum is the leading site for cancer in developed countries and small 
bowel cancers are rare worldwide. The incidence rate of large bowel cancer in 
India is about 7 per 1lakh population and that of incidence rate of small bowel 
cancer is less than 1 per 1lakh population worldwide.
[70]
 The incidence of both 
small and large bowel cancers are low in India.
[53]
 The incidence of colorectal 
cancer in India is 3.6%  when compared worldwide (10%).
[34]
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In our study of 111 cases 90% are large bowel tumours and small bowel 
tumours are only 10%. When compared to benign tumours (7%), malignant 
tumours (93%) are more common. Tumours of intestine were seen over a wide 
range of age group (18 – 75 yrs) with highest distribution in the 4th to 6th decade. 
This correlates with the study done by Abou Zeid AA et al
[2]
 and T. Starzynska et 
al.
[77]
. 
 
SMALL BOWEL NEOPLASMS: 
Small bowel tumours constitute only 1-2% of all gastrointestinal tumours. 
According to Sai Yi Pan et al
[70]
, the incidence of small intestine cancer increasing 
over the past several decades with a four-fold increase for carcinoid tumours, less 
dramatic rise for adenocarcinoma and lymphoma and stable for sarcoma. 
In the present study, the highest distribution of small intestinal neoplasms is 
commonly seen in the age group of 30-50 yrs and shows no sexual predominance. 
In general, higher small intestinal cancer incidence rate have been described 
among males in north America, Europe, Asia and central / south America, with 
exceptions, noted in Iceland, Italy, Poland, Brazil, Australia and Japan, where 
incidence rate are higher among females. But the studies done by David Lewin et 
al
[16]
 and Tadashi Terada et al
[78]
 show a slight male predominance and an average 
age of presentation ranging from 55-63 yrs. This difference in the distribution of 
small intestinal neoplasms might be attributed to the number of cases studied.  
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The male predominance of small intestinal cancers is similar to that 
described for carcinomas at other primary sites, a pattern attributed, in part, to 
environmental, endogenous and behavioural factors that differ by gender.
[62] 
According to Osama Qubaiah et al
[62]
, all histological subtypes of small 
intestine cancers predominated among men with distinct age specific pattern 
among males and females limited to lymphomas. Small intestine lymphomas are 
uniquely characterized by increased incidence in young males but not females. 
Most common presentation of the small intestinal tumour is intestinal 
obstruction. This is in accordance with the study by David Lewin et al.
[16] 
In the present study duodenum is the most common site and the most 
common histological type is adenocarcinoma. In the ileum malignant lymphoma is 
the most common histological type which constitutes more than half of all 
malignancies and the fact correlates well with the study done by Zhou-Zhi-Wei et 
al
[89]
 and Gill SS et al.
[29]
  
In the present study, among 11 cases of small intestinal neoplasms, more 
than 2/3
rd  
are malignant. The incidence of malignant tumours correlates with the 
study done by Ioannis Hatzaras et al.
[36] 
 Of small intestinal tumours 36% are 
adenocarcinoma, 36% of cases are lymphomas, 18% of cases are benign tumours 
and 9% are metastatic malignant melanoma deposit. This correlates with the study 
done by Zhou Zhi-Wei et al.
[89] 
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According to David Lewin et al
[16]
, benign tumours represent approximately 
40% of small intestinal tumours. 30% are smooth muscle stromal tumours, 20% 
are adenomas and 15% are lipomas. Of malignant tumours 33% are 
adenocarcinoma, 33% are carcinoids, 20% are lymphomas and 10% are 
mesenchymal origin. Another study done by Zhou Zhi-Wei et al
[89]
 
adenocarcinoma is the most common tumour followed by malignant lymphoma. 
In our study, we received a small intestine specimen with secondary 
malignant melanoma deposits, primary was from the sole, which is a rare 
occurrence. According to Washington K et al
[83]
, metastatic tumours can involve 
small bowel often in the form of multiple polypoid tumours and may result in 
obstruction or perforation, necessitating palliative resuscitation. The most common 
type of primary tumours is malignant melanoma, carcinoma from lung, breast, 
ovary and choriocarcinoma. Patients with multiple metastases of melanoma usually 
die within 1 year following palliative surgery. But an occasional long term survival 
will be found among those with isolated metastasis.
[86]
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LARGE BOWEL NEOPLASMS: 
 Large bowel cancer is an important public health problem. Each year there 
are nearly one million new cases of colorectal cancer diagnosed worldwide. 
Colorectal cancer related deaths account for more than half a million. According to 
Peter Boyle et al in the United states, colorectal cancer was the most common 
malignancy among persons aged 75 years and older.
[64] 
 Racial and ethnic differences in colon cancer and studies on migrants 
suggest that environmental factors play a key role in the development of the 
disease. 
 The development of large bowel cancer is a multistep process involving 
genetic mutations in mucosal cells, the activation of tumour promoting genes and 
the loss of genes which suppress tumour formation.
[82] 
 Most of the colorectal carcinomas arise from benign adenomatous polyps 
which grow a large size. Those that have villous appearance or contain dysplastic 
cells are most likely to progress to cancer.
[66] 
Individuals with risk factors namely FAP syndromes and inflammatory 
bowel diseases have high risk of developing colorectal tumours but it constitute 
only a small proportion of the overall incidence.
[12,48] 
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 According to Langmann et al, chemopreventive drugs for colorectal 
carcinomas include vitamin A or β carotene, vitamin E, vitamin D, folate, H2 
antagonist, anti-inflammatory drugs and calcium supplements.
[42] 
 Peak incidence of colorectal cancer is 60-79 years. Fewer than 20% of cases 
occur before the age of 50 years.
[9]
 According to Peter Boyle et al,
[64]
 global age 
standardized rates of colorectal carcinoma incidence are higher in men than in 
women. The risk of colorectal cancer rises significantly after the age of 40 years in 
both men and women and doubles in each succeeding decade until the age of 75. 
The median age at diagnosis is 71 years of age.
[24]
 In North America and Australia 
(areas with high rates of colorectal cancer) and in Japan and Italy (countries with 
rapidly raising rates), the age adjusted incidence of colorectal cancer for men 
exceeds women. With lesions in the rectum male: female is 1.2:1. For more 
proximal tumours there is no gender difference.  
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In our study, age group range from 20-75 years (Mean age – 51.4 years). 
Male predominance was seen in all colorectal carcinomas. This is in accordance 
with the study done by Abou Zeid AA et al
[2]
 and T. Starzynska et al.
[77]
 (Table 22) 
 
TABLE – 22  
S.NO STUDIES 
AGE RANGE 
(yrs) 
MEAN AGE 
(yrs) 
1 Abou-zeid et al
[2] 
19 – 74  46 
2 T. Starzynska et al
[77] 
22 – 80  65.4 
3 Yuan-Tzu Lan et al
[87] 
18 – 92  66.9 
4 George E. Theodoropoulos et al
[28]
 45 – 82  63.5 
5 Present study 20 – 75  51.4 
 
 Majority of colonic tumours are seen in the sigmoid colon and the rectum. In 
recent years there is evidence of increasing proportion of proximal tumours. In 
high risk countries colorectal cancer most commonly arises in the recto-sigmoid 
region, but though we fall in the low risk countries we encountered more lesions in 
the distal region may be due to environmental factors or easy approachability 
which made them to be detected at an early stage as many of these are well 
differentiated adenocarcinomas. 
[48]
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TABLE – 23  
 
 In the present study 74 of the 100 colorectal tumours were located in the left 
side (sites being rectum, sigmoid, descending colon and splenic flexure). Most 
common site was rectum with 66% of cases. This is in accordance with the study 
by Osime U et al.
[63]
 (Table 23)  
In the present study bleeding per rectum was the most common clinical 
presentation (55%) of the colorectal tumours.(Table 9) 
LOCATION OF COLORECTAL CARCINOMA IN DIFFERENT STUDIES AS 
PERCENTAGE 
S.NO SITE 
Abdul Kareem FB 
et al (2008)
[1] 
(%) 
Osime U et al 
(1988)
[63] 
(%) 
Qizilbash AH 
(1982)
[68] 
(%) 
Present 
study 
(%) 
1. Caecum 9 2.63 13.53 10 
2. 
Ascending 
colon 
6 2.63 11.28 8 
3. 
Hepatic 
flexure 
0 1.32 1.50 -- 
4. 
Transverse 
colon 
4.5 1.32 4.89 8 
5. 
Splenic 
flexure 
0 1.32 2.63 -- 
6. 
Descending 
colon 
3.6 3.94 6.77 -- 
7. Sigmoid colon 0 7.89 34.21 8 
8. Recto sigmoid 58.8 -- 9.02 -- 
9. Rectum -- 78.95 14.28 66 
Total number of cases 420 76 266 100 
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According to Chen Liu et al, tumours of the caecum and ascending colon 
tend to grow as polypoid exophytic masses. Distal colon carcinomas are annular 
lesions that produce so called „napkin ring‟ constriction of the bowel.[9] 
 
TABLE – 24  
GROWTH PATTERNS OF COLORECTAL ADENOCARCINOMA 
S.NO STUDIES 
 
ULCEROPROLIFERATIVE 
 
(%) 
 
POLYP 
 
(%) 
 
NARROWING 
OF LUMEN 
(%) 
TOTAL 
1. 
Qizilbash 
AH 
(1982)
[68] 
54 28 18 100 
2. 
Present 
study 
82 10 8 100 
   
But most of the tumours in the present study (82%) were ulceroproliferative 
growth in both proximal and distal colon (Table 10).  This correlates with the study 
done by Qizilbash AH.
[68]
 (Table 24) 
In our study of 100 colorectal tumours 95 cases were malignant, remaining 5 
cases were benign, of which 91% were adenocarcinomas. Signet ring cell 
carcinoma, neuroendocrine carcinoma, adenosquamous carcinoma, melanoma 
contributes to 1% each. 
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TABLE – 25  
INCIDENCE OF DIFFERENT TYPES OF MALIGNANT TUMOURS OF COLON 
S.NO STUDIES 
ADENOCARCINOMAS OTHERS 
TOTAL 
No. of cases (%) 
No. of 
cases 
(%) 
1. 
Abdul 
Kareem FB 
et al 
(2008)
[1] 
405  96.4% 15  3.6% 420 
2. 
Osime U et 
al (1988)
[63] 73  96.05% 3  3.95% 76 
3. 
Qizilbash 
AH 
(1982)
[68] 
244  94.9% 13  5.1% 257 
4. 
Present 
study 
91  91% 4  4% 100 
 
 In the present study adenocarcinoma was the most common type of 
malignancy encountered in the colon accounting for 91% of the tumours (Table 
14), a finding that correlates with the study done by various authors. (Table 25) 
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Mucinous tumours are less common and accounts for 10 – 15% of colorectal 
carcinomas. 
TABLE – 26  
INCIDENCE OF MUCINOUS AND NON MUCINOUS ADEENOCARCINOMA 
S.NO STUDIES 
MUCINOUS ADENO 
CARCINOMA 
NON MUCINOUS 
ADENOCARCINOMA 
TOTAL 
No. of 
cases 
(%) 
No. of 
cases 
(%) 
1. 
Qizilbash 
AH 
(1982)
[68] 
14  5 244  91.78 266 
2. 
Osime U et 
al (1988)
[63]
 
4  5.26 69  90.79 76 
3. 
Fazeli MS 
et al 
(2007)
[23] 
71  17.6 332  82.4 403 
4. 
Abdul 
Kareem FB 
et al 
(2008)
[1] 
45  10.7 360  89.3 405 
5. 
Present 
study 
9  9 81  81 100 
 
 In the presemt study mucinous adenocarcinoma constitute about 9%, a 
finding similar to study done by Abdul Kareem FB et al.
[1]
 however the findings 
varied in different studies. (Table 26) 
 Mucinous adenocarcinomas were located in the right side of the colon and 
rectum. It shows a male predominance and mucinous adenocarcinoma patients 
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were younger than adenocarcinoma patients. This is in accordance with the study 
done by J Verhulst et al
[37]
 and Azadeh Safaee et al.
[5] 
 Mucinous adenocarcinoma showed a higher proportion of high grade 
tumours. The adverse prognostic effect of mucinous adenocarcinoma can be 
explained by more advanced stage at presentation. Mucin content when considered 
together with histological grade can be regarded as important prognostic 
indicators.
[56]
 MUC1/DF3 and MUC5/CHL2 immunostaining is useful to 
distinguish between low grade and high grade mucinous adenocarcinoma. MUC2 
and MUC5AC expression may be particularly helpful in predicting the clinical 
outcome of this type.
[57] 
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TABLE - 27 
HISTOLOGICAL GRADE OF ADENOCARCINOMA IN VARIOUS STUDIES 
S.NO STUDIES 
GRADE I GRADE II GRADE III 
TOTAL NO. of 
cases 
(%) 
NO. of 
cases 
(%) 
NO. of 
cases 
(%) 
1. 
Abdul 
Kareem et 
al 
(2008)
[1] 
233 65.6 88 24.7 34 9.5 355 
2. 
Fazeli MS 
et al 
(2007)
[23] 
133 37.6 187 52.8 34 9.6 354 
3. 
Osime V 
et al 
(1988)
[63] 
7 10.14 40 57.97 22 31.88 69 
4. 
Present 
study 
39 44 36 40 5 6 89 
 
 The present study shows higher incidence of well differentiated 
adenocarcinoma, which correlates with the study done by Abdul Kareem FB et 
al.
[1]
 (Table 27) However the findings varied in different studies. 
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TNM STAGING: 
 Pathological TNM staging was carried out for 31 resected specimens in the 
present study. 
TABLE – 28  
TNM STAGING OF ADENOCARCINOMA IN DIFFERENT STUDIES 
S.NO STAGE 
Abdul Kareem 
FB et al (2008)
[1] 
Fazeli MS et al 
(2007)
[23] 
Yuan-Tzu Lan 
et al
[87] Present study 
No. of 
cases 
(%) 
No. of 
cases 
(%) 
No. of 
cases 
(%) 
No. of 
cases 
(%) 
1. I 17 14 33  8.2 
41  
15.9 8  26 
2. II 64 51 193  48.1 
83  
32.2 7  22 
3. III 41 34 134  33.04 
85  
32.9 12  39 
4. IV 1 1 41  10.2 
49  
19 4  13 
TOTAL 123 401 258 31 
 
In the present study stage III was more frequent(39%). This is in accordance 
with the study by Yuan-Tzu Lan et al.
[87]
 (Table 28) 
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p53 IMMUNOEXPRESSION – SMALL INTESTINE: 
p53 expression was studied in 5 small intestinal tumours of which 3 cases 
were adenocarcinoma and 2 cases were lymphomas. p53 expression was quantified 
according to DA Spandidios et al
[15]
 and results were tabulated and analysed. In the 
present study p53 expression is seen in 60% of small intestinal tumours. Of 3 cases 
of adenocarcinoma 2 cases (67%) were p53 positive and 1 out of 2 cases (50%) of 
lymphoma were positive for p53. Intense positivity were seen in lymphomas 
(>50% of cells). This is in accordance with the study done by DA Spandidos et 
al.
[15] 
DA Spandidos et al
[15]
 found immunoreactivity in 46% of small intestinal 
tumours. Ge C, He S, Tian Y[27] reported nuclear positivity for p53 in 75% of small 
intestinal tumours. Tadashi Terada
 [78]
 found 51.21% of p53 positivity in small 
intestinal tumours. M Svrcek et al
[44]
 found p53 positivity in 51.85% of small 
intestinal adenocarcinoma. Krugmann et al
[41]
 reported p53 overexpression in 75% 
of small intestinal lymphomas. These differences may be due to the use of different 
scoring system and inter-observer variability. 
D A Spandidos et al
[15]
 concluded that p53 gene may be involved in the 
pathogenesis of small intestinal tumours.  Tadashi Terada,
[78]
 in his study, found 
that p53 protein overexpression was present in most of the primary small intestinal 
carcinomas.  Ge C et al[27] in their study showed that the degree of p53 protein 
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expression was significantly correlating with the grade of the tumour cell 
differentiation, invasion, metastasis and prognosis. According to Krugmann et al
[41]
 
and Ming Qing et al
[50]
 p53 overexpression in small intestinal lymphomas is a 
critical factor in the transformation of low grade MALT lymphoma and the 
overexpression also indicate the aggressive behavior of high grade tumours. 
p53 immunoexpression was seen in both small intestinal adenocarcinoma 
and lymphoma. Intense positivity was observed in small intestinal lymphoma. This 
shows the involvement of p53 gene in the pathogenesis of small intestinal tumours. 
Due to low sample size, the prognostic value of p53 could not be determined. 
 
p53 IMMUNOEXPRESSION IN COLORECTAL TUMOURS: 
 p53 tumour suppressor gene is one of the most intensively studied tumour 
markers in the colorectal tumours. In this study 30 cases of colorectal carcinoma 
(colectomy specimens) were selected for the study of p53 expression by 
immunohistochemistry in various stages which included 4 mucinous 
adenocarcinomas. For the purpose of statistical analysis stages I and II were 
categorized as low stage and stages III and IV were categorized as high stage. 
According to George E Theodoropoulous et al
[28]
 p53 immunostaining was done 
and the results were tabulated and analysed.  
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TABLE – 29  
S.NO STUDIES 
p53 EXPRESSION 
 
(%) 
1. Mohammad – Reza et al[51] 59 
2. T Starzynska et al
[77] 
46 
3. Scott N et al
[72] 
42 
4. O Petrisor et al
[60] 
66 
5. George E Theodoropoulous et al
[28] 
63.4 
6. Present study 53.3 
 
 In our study 53.3% of colorectal adenocarcinoms showed p53 nuclear 
protein overexpression. These differences may be due to the use of different 
scoring system and inter-observer variability. (Table 29) 
 In the present study p53 expression was more frequent in non-mucinous 
adenocarcinomas (57.7% Vs 25%). (Table 20) This is in accordance with the study 
by Yuan-Tzu-Lan et al
[87]
 who found that 39% of non-mucinous adenocarcinomas 
and 29% of mucinous adenocarcinomas showed p53 positivity and suggesting two 
different pathways, chromosomal instability and microsatellite instability of 
colorectal carcinogenesis respectively. T Starzynska et al
[77]
 studied the relation of 
p53 expression in colorectal carcinoma with histological, clinical, prognostic 
features using follow-up data and concluded that p53 expression occurred as a late 
event and was associated significantly associated with advanced stage of disease, 
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early relapse and death. J Walker et al
[38]
 in their study found that the stage is the 
most accurate prognostic factor for survival. They concluded that p53 
overexpression in colorectal carcinoma correlated with poor prognosis. In this 
study the proportion of p53 nuclear protein expression increases as the stage 
progresses. This association was proved to be statistically significant by using chi 
square test (P < 0.05). This is in accordance with the study done by T Starzynska et 
al,
[77]
 George E Theodoropoulous et al.
[28]
 Several previously published series have 
supported the deleterious effect of p53 over expression.
[26,30,6]
  
Vikos et al studied 41 colorectal tumours showed a significant association 
between elevated p53 and the presence of DNA aneuploidy, a factor that correlated 
with poor prognosis. They also suggested the fact that evaluating p53 expression 
may prove helpful in determining various biological subgroups of colorectal 
carcinomas. Scott N et al
[72]
 analysed 52 colorectal carcinomas in their study and 
found no correlation with p53 overexpression and several factors related to 
prognosis. 
Campo et al (1991)
[7]
 also, did not find relationship between p53 expression 
and degree of differentiation and stage of the tumour, concluded that p53 is not a 
good prognostic indicator in large bowel malignancy. The discrepancies in the 
prognostic role of p53 in colorectal adenocarcinomas might be a result of different 
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kind of materials, methods and antibodies used or differences in the number of 
tumours examined.  
p53 expression increases as the stage progresses, stage is the established 
prognostic factor in colorectal carcinoma, and also there is significant correlation 
between high p53 levels and stage of the colorectal carcinomas, so it can be used 
as a prognostic marker to asses invasiveness and metastatic potential of the 
colorectal tumours. 
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SUMMARY AND CONCLUSION 
 
 This is a retrospective study undertaken in the department of pathology over 
a period of jan 2010 to june 2012. 
 Resected specimens and biopsies of intestinal tumours were included for the 
study. 
 The number of specimen included for the study were 111, 100 from large 
intestine and 11 from small intestine, of which biopsy specimens were 
74(66.67%) and resected specimens were 37(33.33%). 
 Age, sex and site of the lesion were recorded. 
 Incidence of intestinal neoplasms was 2.6% of the total neoplasms in our 
institution.  
 Grading and staging of colorectal carcinomas were done. 
 Immunohistochemistry using p53 antibody was done to assess the role of its 
expression in various types of intestinal tumours. Results were tabulated and 
analysed. 
Small intestinal tumours: 
 Incidence of small intestinal cancer – 0.3%. 
 Age group range from 18 – 70 years with peak incidence in 30 – 50 years. 
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 Most common clinical presentation of small intestinal neoplasm is intestinal 
obstruction (73%). 
 Most of the small bowel neoplasms arise from the duodenum (64%). 
 Of the small intestinal tumours adenocarcinoma and lymphomas have equal 
incidence. 
 p53 gene is involved in the pathogenesis of small intestinal tumours. 
Colorectal tumours: 
 Incidence of colorectal cancer – 2.99% 
 Age group range from 20 – 75 years with peak incidence in 40 – 60 years. 
 Bleeding per rectum is the most common clinical presentation (55%). 
 Most of the colorectal cancer grossly present as ulceroproliferative lesion 
(82%). 
 Rectum is the most common site of occurance (66%) in both sexes. 
 Most of the colorectal tumours show male predominance. 
 Adenocarcinoma is the most common histological type of colorectal tumours 
(80%) followed by mucinous adenocarcinoma (9%). 
 Most of the colorectal adenocarcinoma are well differentiated type. 
 Stag III colorectal adenocarcinoma is more frequent (39%) than other stage. 
 The low stage tumours predominated in both sexes and the high stage 
tumours are common in males. 
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p53: 
 In colorectal tumours p53 expression increases as the stage progresses and 
also there is significant correlation between high p53 levels and stage of colorectal 
carcinomas. So it can be used as a prognostic marker to assess invasiveness and 
metastatic potential of the colorectal tumours. 
 There is a statistically significant correlation between p53 protein expression 
and stage of the colorectal cancer and hence p53 immunoreactivity is an important 
independent prognostic marker in patients with colorectal carcinoma. P53 protein 
overexpression has been associated with a worst overall survival after cancer 
diagnosis. Considering the acceptable reliability and feasibility of detection of p53 
by immunohistochemistry, this marker may be expected to serve as a new genetic 
marker for predicting recurrence and response to chemotherapy in patients with 
colorectal cancer. 
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APPENDIX 
APPENDIX – I 
HAEMATOXYLIN AND EOSIN STAIN 
 
PREPARATION OF SOLUTIONS: 
HARRIS HAEMATOXYLIN 
Distilled water       - 1000ml 
Ammonium alum       - 100g 
Haematoxylin       - 5g 
Absolute ethyl alcohol      - 50ml 
Mercuric oxide       - 2.5g 
100g of ammonium alum is dissolved in 1000ml of distilled water by heating and 
shaking at 60ºC. Add solution of 5g of haematoxylin in 50ml of ethyl alcohol and 
bring rapidly to boil. When it begins to boil, remove from flame and add 2.5g of 
mercuric oxide. Mix by swirling gently. 
EOSIN STAIN 
Eosin Y  - 1g 
Distilled water - 100ml 
Dissolve 1g of eosin in 100ml of water. 
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PROCEDURE: 
1. Dewax the sections through 2 changes of xylene and hydrate the sections 
through descending grades of alcohols to water. 
2. Stain in Harris Haematoxylin for 5 minutes. 
3. Quickly rinse in running water. 
4. Differentiate in 1% acid alcohol (2-3 dips). 
5. Blue the sections in running tap water for 10 minutes. 
6. Stain in 1% aqueous Eosin Y for 30 seconds. 
7. Dehydrate, clear and mount. 
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APPENDIX – II  
IMMUNOHISTOCHEMISTRY 
 
1. 4 micron thick sections were cut from the formalin fixed, paraffin embedded 
tissue sections on slides coated with chrome alum gelatin. 
2. Dewax sections through 2 changes of xylene and hydrate the sections through 
descending grades of alcohol to water. 
3. Slides are placed in antigen retrieval buffer solution (Tris EDTA / Citrate 
buffer) inside microwave oven at required temperature and time. 
4. Wash in running tap water for 5 minutes. 
5. Slides are immersed in hydrogen peroxide for 10 minutes to block endogenous 
peroxidase activity. 
6. Wash in Tris buffer solution for 5 minutes. 
7. Slides are placed in power block reagent for 10 minutes to block nonspecific 
reaction with other tissue antigens. 
8. Slides are drained and covered with the concerned primary antibody for one 
hour. 
9. Wash in Tris buffer solution for 5 minutes. 
10. Slides are placed in super enhancer solution for 30 minutes to enhance the 
reaction between primary and secondary antibodies. 
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11. Wash in Tris buffer solution for 5 minutes. 
12. Place in enzyme labeled polymer secondary antibody (super sensitive poly 
HRP) for 30 minutes. 
13. Wash in Tris buffer solution for 5 minutes. 
14. Diamino benzidine (DAB) was used as chromogen. 
15. Wash in distilled water for 2-4 minutes. 
16. Counter stained with Harris haematoxylin for 1 minute. 
17. Cleared in xylene, mounted. 
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S.NO 
BIOPSY 
NO 
AGE SEX BPR 
ALT 
BH 
LOW SITE CONFIGURATION HPE GRADE STAGE p53 
1 214/10 40 F Y N N RECTUM ULCERO-PROLIFERATIVE MUCINOUS CARCINOMA 
  
 
2 267/10 32 M N Y N 
ASCENDING 
COLON 
ULCERO-PROLIFERATIVE 
NEUROENDOCRINE 
CARCINOMA   
 
3 495/10 30 F Y N N RECTUM ULCERO-PROLIFERATIVE 
ADENOSQUAMOUS 
CARCINOMA   
 
4 573/10 60 F Y N N RECTUM ULCERO-PROLIFERATIVE ADENOCARCINOMA I 
 
 
5 725/10 60 M N N Y RECTUM ULCERO-PROLIFERATIVE ADENOCARCINOMA I 
 
 
6 816/10 38 M Y N N RECTUM ULCERO-PROLIFERATIVE ADENOCARCINOMA I 
 
 
7 968/10 36 M N Y Y RECTUM ULCERO-PROLIFERATIVE ADENOCARCINOMA I 
 
 
8 1045/10 45 M N Y N RECTUM ULCERO-PROLIFERATIVE ADENOCARCINOMA I 
 
 
9 1179/10 73 M N Y N 
TRANSVERSE 
COLON 
ULCERO-PROLIFERATIVE ADENOCARCINOMA II 
 
 
10 1281/10 65 M Y N N RECTUM NARROWING OF LUMEN ADENOCARCINOMA I 
 
 
11 1494/10 44 M Y N N 
ASCENDING 
COLON 
ULCERO-PROLIFERATIVE MUCINOUS CARCINOMA 
  
 
12 1670/10 58 M N Y N SIGMOID COLON NARROWING OF LUMEN ADENOCARCINOMA I 
 
 
13 1791/10 56 M Y N N RECTUM POLYP ADENOCARCINOMA I 
 
 
14 1917/10 45 F Y N N RECTUM ULCERO-PROLIFERATIVE ADENOCARCINOMA I 
 
 
15 2155/10 46 M Y N N RECTUM ULCERO-PROLIFERATIVE ADENOCARCINOMA II 
 
 
16 2267/10 73 M Y N N RECTUM NARROWING OF LUMEN ADENOCARCINOMA I 
 
 
17 2323/10 60 M N Y N RECTUM ULCERO-PROLIFERATIVE ADENOCARCINOMA II 
 
 
18 2453/10 39 M Y N N RECTUM ULCERO-PROLIFERATIVE ADENOCARCINOMA I 
 
 
19 2548/10 51 F Y N N CAECUM ULCERO-PROLIFERATIVE ADENOCARCINOMA II 
 
 
20 2641/10 40 F N Y N CAECUM ULCERO-PROLIFERATIVE MUCINOUS CARCINOMA 
  
 
21 2689/10 39 M N Y N RECTUM POLYP ADENOCARCINOMA I 
 
 
22 2751/10 48 M N Y N RECTUM ULCERO-PROLIFERATIVE ADENOCARCINOMA I 
 
 
23 2782/10 65 F Y N N RECTUM ULCERO-PROLIFERATIVE ADENOCARCINOMA II 
 
 
24 2783/10 37 M Y N N RECTUM ULCERO-PROLIFERATIVE ADENOCARCINOMA I 
 
 
25 2807/10 44 M N Y N RECTUM ULCERO-PROLIFERATIVE ADENOCARCINOMA III 
 
 
26 2969/10 71 M Y N Y SIGMOID COLON POLYP ADENOCARCINOMA II 
 
 
27 3020/10 58 M Y Y N RECTUM ULCERO-PROLIFERATIVE ADENOCARCINOMA II 
 
 
28 3046/10 40 F N Y Y RECTUM ULCERO-PROLIFERATIVE ADENOCARCINOMA II 
 
 
29 3209/10 53 M Y N N 
TRANSVERSE 
COLON 
ULCERO-PROLIFERATIVE ADENOCARCINOMA II 
IV 
(T4N1M1) 
(M-Ovary) 
+ 
30 3297/10 53 M N Y N RECTUM ULCERO-PROLIFERATIVE ADENOCARCINOMA I 
 
 
31 3333/10 45 F N Y N RECTUM NARROWING OF LUMEN ADENOCARCINOMA I 
III 
(T3N1M0) 
+ 
32 3426/10 40 F Y N N RECTUM ULCERO-PROLIFERATIVE ADENOCARCINOMA II 
 
 
33 3460/10 60 M N Y Y SIGMOID COLON ULCERO-PROLIFERATIVE ADENOCARCINOMA I 
III 
(T3N1M0) 
+ 
34 3484/10 53 M N N Y RECTUM ULCERO-PROLIFERATIVE ADENOCARCINOMA II 
I 
(T2N0M0) 
- 
35 3536/10 45 F N Y N RECTUM ULCERO-PROLIFERATIVE ADENOCARCINOMA II 
 
 
36 3679/10 46 M Y N N RECTUM POLYP ADENOCARCINOMA II 
 
 
37 3807/10 50 F N Y N RECTUM ULCERO-PROLIFERATIVE ADENOCARCINOMA I 
 
 
38 3812/10 42 M N Y N RECTUM ULCERO-PROLIFERATIVE ADENOCARCINOMA I 
 
 
39 3819/10 43 M Y N N RECTUM POLYP TUBULOVILLOUS 
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40 3830/10 52 M Y N N RECTUM ULCERO-PROLIFERATIVE ADENOCARCINOMA II 
 
 
41 3844/10 55 M Y N N RECTUM ULCERO-PROLIFERATIVE ADENOCARCINOMA I 
 
 
42 4023/10 50 M N N Y RECTUM ULCERO-PROLIFERATIVE ADENOCARCINOMA III 
 
 
43 4044/10 40 M N Y N RECTUM ULCERO-PROLIFERATIVE ADENOCARCINOMA I 
I 
(T1N0M0) 
- 
44 4127/10 43 M Y N N RECTUM POLYP TUBULAR ADENOMA 
  
 
45 4192/10 70 F N Y N 
ASCENDING 
COLON 
ULCERO-PROLIFERATIVE ADENOCARCINOMA 
 
III 
(T3N1M0) 
+ 
46 4261/10 35 F Y N N 
ASCENDING 
COLON 
ULCERO-PROLIFERATIVE MUCINOUS CARCINOMA 
  
 
47 4364/10 75 F N N Y RECTUM ULCERO-PROLIFERATIVE 
TUBULOVILLOUS 
ADENOMA   
 
48 4365/10 53 M N Y N 
TRANSVERSE 
COLON 
ULCERO-PROLIFERATIVE MUCINOUS CARCINOMA 
  
 
49 113/11 51 F N Y N RECTUM ULCERO-PROLIFERATIVE 
S/O MALIGNANT 
MELANOMA   
 
50 218/11 57 M N Y N 
TRANSVERSE 
COLON 
ULCERO-PROLIFERATIVE ADENOCARCINOMA II 
III 
(T4N2M0) 
+ 
51 364/11 40 F Y N N SIGMOID COLON ULCERO-PROLIFERATIVE ADENOCARCINOMA I 
II 
(T3N0M0) 
- 
52 417/11 62 M Y N N RECTUM ULCERO-PROLIFERATIVE ADENOCARCINOMA I 
 
 
53 722/11 42 M Y N N 
ASCENDING 
COLON 
ULCERO-PROLIFERATIVE ADENOCARCINOMA II 
 
 
54 785/11 60 M N Y N RECTUM ULCERO-PROLIFERATIVE ADENOCARCINOMA I 
 
 
55 823/11 67 M Y N N 
ASCENDING 
COLON 
POLYP ADENOCARCINOMA II 
 
 
56 862/11 67 M Y N Y CAECUM ULCERO-PROLIFERATIVE ADENOCARCINOMA II 
III 
(T3N1M0) 
+ 
57 1236/11 28 F N Y N SIGMOID COLON ULCERO-PROLIFERATIVE ADENOCARCINOMA II 
II 
(T4N0M0) 
- 
58 1250/11 41 M Y N N SIGMOID COLON ULCERO-PROLIFERATIVE ADENOCARCINOMA II 
IV 
(T3N1M1) 
(M-Liver) 
+ 
59 1439/11 50 M Y N N RECTUM ULCERO-PROLIFERATIVE ADENOCARCINOMA I 
 
 
60 1645/11 55 F Y N Y RECTUM ULCERO-PROLIFERATIVE ADENOCARCINOMA I 
I 
(T2N0M0) 
+ 
61 1689/11 70 F Y N N CAECUM ULCERO-PROLIFERATIVE MUCINOUS CARCINOMA 
 
II 
(T3N0M0) 
- 
62 1840/11 40 M Y N N RECTUM ULCERO-PROLIFERATIVE ADENOCARCINOMA III 
 
 
63 1992/11 45 F N Y N RECTUM ULCERO-PROLIFERATIVE ADENOCARCINOMA I 
 
 
64 2037/11 40 M Y N N RECTUM ULCERO-PROLIFERATIVE ADENOCARCINOMA III 
IV 
(T3N1M1) 
(M-Ovary) 
+ 
65 2124/11 65 M Y N N RECTUM NARROWING OF LUMEN ADENOCARCINOMA II 
I 
(T2N0M0) 
- 
66 2836/11 60 F N Y N CAECUM POLYP ADENOCARCINOMA I 
 
 
67 2937/11 65 F Y N N CAECUM ULCERO-PROLIFERATIVE ADENOCARCINOMA I 
I 
(T2N0M0) 
- 
68 3101/11 49 F N N Y CAECUM ULCERO-PROLIFERATIVE ADENOCARCINOMA I 
III 
(T2N2M0) 
- 
69 3232/11 70 M Y N N RECTUM ULCERO-PROLIFERATIVE ADENOCARCINOMA I 
 
 
70 3384/11 40 M Y N N 
TRANSVERSE 
COLON 
ULCERO-PROLIFERATIVE ADENOCARCINOMA I 
IV 
(T4N1M1) 
(M-Liver) 
 
- 
71 3461/11 42 F N Y N SIGMOID COLON ULCERO-PROLIFERATIVE ADENOCARCINOMA II 
II 
(T3N0M0) 
+ 
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72 3701/11 66 F Y N N RECTUM ULCERO-PROLIFERATIVE VILLOUS ADENOMA 
  
 
73 3798/11 30 M N N Y 
ASCENDING 
COLON 
ULCERO-PROLIFERATIVE 
SIGNET RING CELL 
CARCINOMA   
 
74 3813/11 55 M Y N N RECTUM ULCERO-PROLIFERATIVE ADENOCARCINOMA III 
 
 
75 4073/11 50 M N Y N RECTUM ULCERO-PROLIFERATIVE MUCINOUS CARCINOMA 
 
II 
(T3N0M0) 
- 
76 4227/11 39 M Y N N RECTUM ULCERO-PROLIFERATIVE MUCINOUS CARCINOMA 
 
III 
(T3N1M0) 
- 
77 4229/11 45 F Y N N RECTUM ULCERO-PROLIFERATIVE ADENOCARCINOMA 
  
 
78 4272/11 55 M N N Y RECTUM ULCERO-PROLIFERATIVE ADENOCARCINOMA I 
 
 
79 4289/11 45 F Y N N RECTUM NARROWING OF LUMEN ADENOCARCINOMA II 
II 
(T3N0M0) 
+ 
80 4509/11 55 M Y N N RECTUM ULCERO-PROLIFERATIVE ADENOCARCINOMA II 
I 
(T2N0M0) 
 
81 4324/11 70 M Y N N RECTUM ULCERO-PROLIFERATIVE ADENOCARCINOMA II 
 
 
82 4392/11 70 M N Y N RECTUM ULCERO-PROLIFERATIVE ADENOCARCINOMA II 
 
 
83 4529/11 67 M N Y N RECTUM ULCERO-PROLIFERATIVE ADENOCARCINOMA II 
 
 
84 4737/11 50 F N Y N CAECUM ULCERO-PROLIFERATIVE ADENOCARCINOMA II 
 
 
85 4798/11 65 M Y N N RECTUM ULCERO-PROLIFERATIVE VILLOUS ADENOMA 
  
 
86 67/12 68 F N N Y CAECUM ULCERO-PROLIFERATIVE ADENOCARCINOMA II 
 
 
87 194/12 52 F N Y N RECTUM ULCERO-PROLIFERATIVE ADENOCARCINOMA I 
 
 
88 315/12 65 F Y N N RECTUM ULCERO-PROLIFERATIVE ADENOCARCINOMA II 
 
 
89 419/12 45 F Y N N RECTUM ULCERO-PROLIFERATIVE ADENOCARCINOMA I 
 
 
90 519/12 65 F N N Y RECTUM NARROWING OF LUMEN ADENOCARCINOMA II 
III 
(T3N1M0) 
+ 
91 559/12 50 F Y N N RECTUM POLYP ADENOCARCINOMA II 
 
 
92 610/12 60 M N Y N RECTUM ULCERO-PROLIFERATIVE ADENOCARCINOMA I 
I 
(T2N0M0) 
- 
93 722/12 40 M Y N N 
ASCENDING 
COLON 
ULCERO-PROLIFERATIVE ADENOCARCINOMA II 
II 
(T3N0M0) 
- 
94 723/12 38 M Y N N 
TRANSVERSE 
COLON 
POLYP ADENOCARCINOMA II 
 
 
95 1027/12 20 M N Y N 
TRANSVERSE 
COLON 
ULCERO-PROLIFERATIVE MUCINOUS CARCINOMA 
 
III 
(T3N2M0) 
+ 
96 1189/12 55 M N Y N CAECUM ULCERO-PROLIFERATIVE ADENOCARCINOMA I 
I 
(T2N0M0) 
+ 
97 1384/12 45 F N Y N 
TRANSVERSE 
COLON 
ULCERO-PROLIFERATIVE ADENOCARCINOMA I 
 
 
98 1522/12 70 M Y N N RECTUM NARROWING OF LUMEN ADENOCARCINOMA II 
III 
(T3N1M0) 
+ 
99 1992/12 62 M Y N N RECTUM ULCERO-PROLIFERATIVE ADENOCARCINOMA I 
III 
(T4N1M0) 
- 
100 2120/12 45 M Y N N SIGMOID COLON ULCERO-PROLIFERATIVE ADENOCARCINOMA II 
III 
(T3N1M0) 
+ 
 
 
 
 
 
 
HPE – Histopathological examination   LOW – Loss of weight 
BPR – Bleeding per rectum    ALT BH – Altered bowel habits 
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S.NO 
BIOPSY 
NO 
AGE SEX SYMPTOMS SITE HPE GRADE P53 
1 1093/10 52 M INTESTINAL OBSTRUCTION ILEUM NHL/MALTOMA 
  
2 211/11 56 M INTESTINAL OBSTRUCTION JEJUNUM MALIGNANT MELANOMA DEPOSIT 
  
3 273/11 27 M INTESTINAL OBSTRUCTION DUODENUM NHL 
  
4 302/11 40 F INTESTINAL OBSTRUCTION DUODENUM BENIGN GIST 
  
5 381/11 3 F ABDOMINAL MASS DUODENUM BURKITT LYMPHOMA 
 
- 
6 888/11 50 M INTESTINAL OBSTRUCTION DUODENUM ADENOCARCINOMA II + 
7 1677/11 35 F BLEEDING PER RECTUM DUODENUM ADENOCARCINOMA II - 
8 1933/11 50 M INTESTINAL OBSTRUCTION DUODENUM ADENOCARCINOMA II 
 
9 2092/11 32 F ABDOMINAL PAIN DUODENUM ADENOCARCINOMA I + 
10 4726/11 50 M INTESTINAL OBSTRUCTION ILEUM MALT-LYMPHOMA 
 
+ 
11 1538/12 70 M INTESTINAL OBSTRUCTION JEJUNUM MULTIPLE LIPOMA 
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Figure 01: Multiple lipomatous polyp – Jejunum
 
Figure 02: Malignant melanoma deposits – Jejunum showing multiple localized polypoid 
lesions  
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Figure 03: Ulceroproliferative growth sigmoid colon – Adenocarcinoma
 
Figure 04: Malignant melanoma deposits – Jejunum showing sheets of atypical 
melanocytes with nuclear pleomorphism and prominent nucleoli with 
intracytoplasmic melanin pigment infiltrating into the submucosa [10X] 
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Figure 05:  Well differentiated adenocarcinoma – Duodenum showing tubular glands lined 
by malignant cells [10X]
 
Figure 06: MALT Lymphoma – Ileum shows diffuse sheets of large atypical 
cells with irregular nuclear contour. Normal glands are seen above the lesion 
[10X] 
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Figure 07: Well differentiated adenocarcinoma – Colon showing easily discernible tubule 
formation and basally oriented nuclei [10X]
 
Figure 08: Moderately differentiated adenocarcinoma – Colon exhibiting a 
complex and irregular tubular pattern with some loss of nuclear polarity [10X] 
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Figure 09: Poorly differentiated adenocarcinoma – Rectum showing diffuse sheets of 
malignant cells [10X]
 
Figure 10: Mucinous adenocarcinoma – Colon showing malignant cells floating in 
mucinous pool [10X] 
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Figure 11: Stage I Colorectal carcinoma p53 Negative [10X] 
 
Figure 12: 23 StageI Colorectal carcinoma p53 Positive [40X] 
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Figure 13: Stage II Colorectal carcinoma p53 Negative [10X] 
 
Figure 14: stageII Colorectal carcinoma p53 Positive [40X] 
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Figure 15: Stage III Colorectal carcinoma p53 Negative [10X] 
 
Figure 16: StageIII Colorectal carcinoma p53 Positive [40X] 
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Figure 17: Stage IV Colorectal carcinoma p53 Negative [10X] 
 
Figure 18: Stage IV Colorectal carcinoma p53 Positive [40X] 
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Figure 19: Mucinous adenocarcinoma p53 negative [40X] 
 
Figure 20: Mucinous adenocarcinoma p53 Positive [40X]  
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Figure 21: Small intestine adenocarcinoma p53 Positive [40X] 
 
Figure 22: Small intestine Lymphoma p53 Positive [40X] 
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